Back to Markets
View all Q&A →
Earnings● Neutral
$BIIB Q1 Earnings Hit by $34M in R&D Charges
Biogen expects a $0.19 per share reduction in net income from R&D costs. With an Alpha Score of 54, investors should watch the April 30 formal earnings release.
Continue with
AlphaScala Research Snapshot
Live stock context for companies directly referenced in this story
Alpha Score of 50 reflects weak overall profile with strong momentum, weak value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Alpha Score
50
Weak
This panel uses AlphaScala-native stock data — proprietary scoring and live snapshots.
Biogen has issued a preliminary warning regarding its first-quarter financial results, citing an expected negative impact on net income. The biotechnology company projects a reduction of approximately $0.19 per share due to in-process research and development (IPR&D) charges totaling roughly $34 million. These adjustments are being disclosed ahead of the company’s formal first-quarter earnings report, which is scheduled for release on April 30.
How this story was producedLast reviewed Apr 6, 2026
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.
Explore More
More from AlphaScala
Trading Q&A
How to start trading stocks as a beginner?
What is the S&P 500 index?
What is an ETF and how does it work?
What is a hedge fund?